-
Indivior study finds higher SUBLOCADE dose aids fentanyl users
-
S&P announces index changes affecting dozens of companies across three indices
-
Indivior pays $295 million to conclude DOJ matter
-
Indivior presents data on monthly injectable buprenorphine benefits
-
Indivior PLC (INDV) Tops Q3 EPS by 33c ; Offers Guidance
-
SUBLOCADE study shows higher retention rates with rapid induction method
-
Indivior plans move from UK to US through new Delaware parent company
-
Indivior (INDV) PT Raised to $34 at Craig-Hallum
-
Piper Sandler Reiterates Overweight Rating on Indivior (INDV)
-
Indivior PLC (INDV) Tops Q2 EPS by 27c; raises guidance
-
Jefferies Assumes Indivior (INDV) at Buy
-
Indivior (INDV) adds Tony Kingsley to Board
-
Indivior (INDV) names Patrick Barry as CCO
-
Indivior PLC (INDV) Tops Q1 EPS by 16c
-
Indivior (INDV) Announces Board Changes
-
Indivior PLC (INDV) Tops Q4 EPS by 6c, Offers Guidance
-
Rodman & Renshaw Starts Indivior (INDV) at Buy
-
Indivior (INDV) Highlights Growing Body of Data on SUBLOCADE
-
Indivior (INDV) PT Raised to $16 at Piper Sandler
-
Piper Sandler Reiterates Overweight Rating on Indivior (INDV)
-
Indivior (INDV) Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance
-
Indivior's (INDV) SUBLOCADE Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
-
Indivior (INDV) PT Lowered to $20 at Craig-Hallum
-
Piper Sandler Reiterates Overweight Rating on Indivior (INDV)
-
Indivior (INDV) Announces BARDA's First Order of OPVEE to Combat Opioids and Aid in National Preparedness
-
Indivior (INDV) Announces New $100M Share Buyback
-
Piper Sandler Starts Indivior (INDV) at Overweight
-
Indivior (INDV) PT Lowered to $24 at Craig-Hallum
-
Indivior (INDV) lowers guidance

